Agent Capital

About The Fund

Agent Capital is a healthcare venture capital firm based in Waltham, Massachusetts, with a focus on investing in novel, differentiated biotechnology and healthcare therapeutics and treatments that address unmet patient needs. They invest across various stages of company development, aligning themselves with scientists, entrepreneurs, and other investors to advance healthcare innovations positively impacting patients' lives. Agent Capital targets investment in therapeutics for conditions with the highest unmet medical need, such as cancer, aging, rare diseases, and neurodegeneration. Their investment strategy excludes interest in 'me too' therapies or those for conditions well managed by existing medicines. Agent Capital typically concentrates on key investment areas including Rare Diseases, Oncology, Neurology, and Immunology. Their approach is proactive, guiding biotech companies to significant milestones and exits. With a balance of investment across stages and types, they commit to investments that progress healthcare. The fund specializes in early to late-stage investments, including Seed, Pre-seed, Series A, and Series B rounds, and has a preferred investment range with a minimum of $250,000, a maximum of $15,000,000, and a 'sweet spot' of around $7,500,000. The portfolio highlights include companies like Dice Therapeutics, Freenome, Metagenomi, and Dragonfly Therapeutics, among others. Agent Capital's proven strategy is reflected in their active portfolio and selective news coverage highlighting industry collaboration and innovative clinical trial results, such as the work by Palvella Therapeutics.